Pre-T2D IPFP-ASCs demonstrated a significant reduction in CD90 and CD105 compared to Non-T2D and T2D IPFP-ASCs without a corresponding increase in CD3, CD14, CD31, or CD45 expression (Figure 1A, Supplementary Figure S1). This evidence concerns the gene THY1 and type 2 diabetes mellitus.